Regen BioPharma Inc (RGBP): R&D Expense
$11.7K
Year ended 2025-09-30
$223.9K
Trailing 12 months to 2026-06-30
-58.0%
3-year compound annual growth
-2.5%
5-year compound annual growth
-27.2%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $11.7K | -92.4% | 2025-12-30, From 2024-10-01 |
| 2024-09-30 | $153.7K | -27.6% | 2025-12-30, From 2023-10-01 |
| 2023-09-30 | $212.3K | +34.2% | 2025-05-13, From 2022-10-01 |
| 2022-09-30 | $158.1K | +330.8% | 2023-11-20, From 2021-10-01 |
| 2021-09-30 | $36.7K | +176.3% | 2022-11-15, From 2020-10-01 |
| 2020-09-30 | $13.3K | -70.9% | 2021-12-22, From 2019-10-01 |
| 2019-09-30 | $45.6K | -87.8% | 2021-08-04, From 2018-10-01 |
| 2018-09-30 | $374.4K | -67.4% | 2021-06-21, From 2017-10-01 |
| 2017-09-30 | $1.15M | +71.3% | 2018-12-27, From 2016-10-01 |
| 2016-09-30 | $671.1K | +137.7% | 2016-12-21, From 2015-10-01 |
| 2015-09-30 | $282.3K | n/m | 2016-12-21, From 2014-10-01 |
| 2014-09-30 | $23.9K | +184.3% | 2017-04-28, From 2013-10-01 |
| 2013-09-30 | $8.4K | n/a | 2014-12-18, From 2012-10-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Regen BioPharma Inc (RGBP) | 2025-09-30 | $11.7K | -92.4% |
| Clene Inc. (CLNN) | 2025-12-31 | $14.01M | -30.1% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $121.1K | -32.5% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $588.3K | +106.1% |
| Allarity Therapeutics, Inc. (ALLR) | 2025-12-31 | $6.60M | +8.3% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $7.95M | -29.9% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $6.69M | +16.3% |
| Medicinova Inc (MNOV) | 2025-12-31 | $6.70M | -1.5% |
Compare RGBP, CLNN, ABVC, HIND side by side · Screen every company in Pharmaceutical Preparations ↗